Willenken Recognized by Benchmark Litigation for the Seventh Consecutive Year

    Willenken and its partners Eileen Ahern, Paul Loh, Amelia Sargent, and Jason Wilson are once again featured by Benchmark Litigation, a leading guide that ranks elite litigation firms in North America for their excellence in litigation and client service.

    In the 2024 Benchmark Litigation edition, Willenken is recognized as a “Recommended” firm for litigation and dispute resolution. Partners Eileen Ahern, Paul Loh, Amelia Sargent, and Jason Wilson are each recognized as Litigation Stars. This ranking is reserved for lawyers who are consistently recommended as reputable and effective litigators by clients and peers.

    Clients spoke candidly to Benchmark Litigation researchers about their experience with the firm describing the firm as a litigation-specific shop that is noted for its “trial acumen with California-centric cases” and lauded for its “efficient staffing, effective strategies and excellent communications.” Clients characterize the firm’s attorneys as “excellent in terms of providing responsive, cost-efficient, and insightful services that are always geared toward obtaining the best result at the earliest juncture.”

    Benchmark Litigation states that “Paul Loh has been acknowledged as the firm’s premier trial lawyer, with more than 110 cases under his belt. He notched another win last year, leading a team that secured a significant trial victory on behalf of AbbVie Endocrine in the first phase of a high-stakes breach-of-contract case in Delaware Chancery Court against Takeda Pharmaceutical Company, accusing Takeda of failing to supply AbbVie’s requirements for Lupron, an androgen deprivation therapy entity. After a Food and Drug Administration inspection found serious quality deficiencies at one of Takeda’s Japanese Lupron manufacturing facilities, production disruptions caused a worldwide Lupron supply shortage. The phase-two trial was held in January 2023 to determine the amount of damages to be awarded to AbbVie for Takeda’s breaches of the parties’ Lupron supply agreement. Closing arguments were heard in Delaware Chancery Court in May. The Delaware Court of Chancery sided with AbbVie in September 2023, granting the drugmaker nearly all of the $480.6 million it was seeking in damages.”

    Benchmark Litigation also reports that “[o]ther members of the team include Jason Wilson and Amelia Sargent, both of whom have been increasingly stepping to the fore and burnishing their battle-ready credentials. Jason has a history of taking on really difficult cases for California-centric clients. Wilson is defending SoCalGas and Sempra Energy in a lawsuit alleging claims of negligence and inverse condemnation. The plaintiffs allege that the other defendants in this case constructed a back house on the plaintiffs’ property, in close proximity to the clients’ gas service line, which caused stress on the pipe that resulted in the pipe bending and cracking and leaking natural gas. This natural gas eventually seeped into the plaintiffs’ property’s foundation and structure and was ignited by an unknown source. Wilson also represents long-time client McDonald’s in a lawsuit against a car wash, alleging causes of action for nuisance, trespass, declaratory relief, and permanent injunction.”

    See Benchmark Litigation’s full coverage of the firm here.

    ABOUT BENCHMARK LITIGATION

    Now in its 17th year of publication, Benchmark Litigation is the only independent guide focused exclusively on identifying and ranking leading litigation attorneys and firms at the local and national levels in North America. The ranking results are the culmination of a six-month research period during which researchers conduct extensive interviews with litigators and their clients. The researchers examine recent casework handled by the firms and ask sources to offer their professional opinions on litigators practicing within their state or national practice areas.

    up next...

    Willenken Recognized As Top Firm to Work for by Los Angeles Business Journal for the Fourth Consecutive Year

    September 18, 2023